JPMorgan analyst Anupam Rama double downgraded CytomX Therapeutics to Underweight from Overweight without a price target. Sentiment on the shares has shifted to a "show-me-story," post multiple clinical setbacks over the last 12 months for key assets, Rama tells investors in a research note. The analyst sees CytomX as a relative underperformer versus the broader biotech space.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics reports Q3 EPS (35), consensus (31c)
- CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
- CytomX Therapeutics to Present at Upcoming November Investor Conferences
- CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
